Connect your AI

Veracyte VCYT 2030

2030 at other companies

Guardant HealthGH

——

Natera, Inc.NTRA

——

RevvityRVTY

——

Labcorp HoldingsLH

——

Agilent TechnologiesA

——

AbbottABT

——

Other financials

Income statement

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

Market cap$4.29B+10.7%

Profitability

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's 2030.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veracyte's 2030?: Veracyte (VCYT) reported 2030 of $11.72M in Q1 2026.
How has Veracyte's 2030 changed year-over-year?: Veracyte's 2030 decreased by 2.6% year-over-year, from $12.03M to $11.72M.